Abstract 296P
Background
Despite the knowledge that HPV is responsible for high-grade CIN and cervical cancer, little is known about the use of therapeutic vaccines as treatment considering most studies are still in early stages. We aimed to synthesize and critically evaluate the evidence from clinical trials on the safety, efficacy, and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade CIN associated with HPV.
Methods
A systematic review of clinical trials adhering to the PRISMA 2020 statement was undertaken in MEDLINE/PubMed, Embase, CENTRAL Cochrane, Web-of-Science, Scopus, and LILACS, with no data or language restriction. Primary endpoint related to the safety, efficacy, and immunogenicity of these vaccines were assessed by analyzing the adverse/toxic effects associated with the therapeutic vaccine administration; via histopathological regression of the lesion and/or regression of the lesion size and by viral clearance; and through the immunological response of individuals who received treatment compared to those who did not or before and after receiving the vaccine, respectively.
Results
A total of 1,184 studies were identified, and 16 met all criteria. Overall, the therapeutic vaccines were heterogeneous regarding their formulation, dose, intervention protocol and routes of administration making meta-analysis unfeasible. In most studies (n=15), the vaccines were safe and well tolerated, with clinical efficacy with regards to lesions and histopathological regression or viral clearance. In addition, 11 studies showed favorable immunological responses against HPV, and seven studies showed a positive correlation between immunogenicity and clinical response, indicating promising results that should be further investigated.
Conclusions
Therapeutic vaccines, although urgently needed for avoid progression of CIN 2/3 patients, still present sparse data, requiring greater investments in well-designed phase III RCT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
362P - Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC)
Presenter: Irene Braña
Session: Poster Display
Resources:
Abstract
363P - Effect of financial distress and mental well-being of patients with early vs advanced oral cancer on informal caregiver's quality of life: A prospective real-world data from public health sector hospital
Presenter: Abhinav Thaduri
Session: Poster Display
Resources:
Abstract
364P - Artificial intelligence provides more accurately neck lymph nodes auto-segmentation in radiotherapy
Presenter: chiencheh Chen
Session: Poster Display
Resources:
Abstract
365P - Radiotherapy treatment outcomes and treatment compliance of nasopharyngeal cancer patients in Sabah: A retrospective analysis
Presenter: Anbarasan Anbazagan
Session: Poster Display
Resources:
Abstract
366P - Pre-treatment oral fungal microbiome and nasopharyngeal carcinoma prognosis: A population-based cohort study in southern China
Presenter: Yufeng Chen
Session: Poster Display
Resources:
Abstract
367P - Prevalence and association of sarcopenia with mortality in patients with head and neck cancer: A meta-analysis
Presenter: Claire Lim
Session: Poster Display
Resources:
Abstract
368P - Distinct gene expression profiling explored using nanostring tumor signalling 360 panel with validations in different clinical stages of oral submucous fibrosis patients: A first Indian study
Presenter: Yasasve Madhavan
Session: Poster Display
Resources:
Abstract
370P - Low-dose nivolumab with induction chemotherapy for inoperable HNSCC in 111 patients: Response rates, survival, and implications for LMICs
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
371P - The role of FDG-PET/CT in the assessment of response to radiation therapy in head and neck cancers: A systematic review and meta-analysis
Presenter: Felix Wijovi
Session: Poster Display
Resources:
Abstract
372P - Effectiveness of HAN-MI-RADS (head and neck molecular imaging-reporting and data system) criterion in head and neck squamous cell carcinoma post concurrent chemoradiotherapy
Presenter: Manoj Gupta
Session: Poster Display
Resources:
Abstract